Market Report Source

Overview

Introduction
Mixed Urinary Incontinence (MUI) affects over 10% of women, with women suffering from unpleasant symptoms of both urge urinary incontinence (UUI) and stress urinary incontinence (SUI). At present, no pharmacological agent is able to effectively treat the symptoms of both UUI and SUI.

Scope
Quantitative treatment data from 288 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to third-line treatments for MUI
Influences on treatment choice and perception of current drug therapies including darifenacin, solifenacin and duloxetine
Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline

Highlights
Approximately only half of women with MUI seek treatment for their condition. Of these women, less than half receive an accurate diagnosis on first presentation to a physician. Drug manufacturers are therefore failing to maximize revenues. A need for better education of both patients and physicians exists.

With approximately a third of patients most distressed by their SUI symptoms, opportunities still exist for manufacturers with a pharmacological treatment for SUI to establish themselves as physicians’ first-line treatment option for MUI.

Drug treatment rates are higher in MUI overall than in other urinary incontinence disorders, which may favor this market for novel product launches.

Reasons to Purchase
Forecast product sales by understanding key aspects of MUI epidemiology, diagnosis and treatment
Gain a better understanding of the challenges facing current and future players in the MUI market
Identify physicians key concerns in MUI including unmet needs and the attributes that physicians believe are desirable for future treatments”

Table of Contents

TABLE OF CONTENTS
OVERVIEW
This product has been designed for delivery in a slide pack format (PowerPoint).
Please select the slide pack option from the download menu at the side of the page
Introduction
Scope of this report
Research and analysis highlights
Key reasons to read this report
APPENDIX A
Research methodology
Physician Sample breakdown
Urinary Incontinence and Overactive Bladder Insight Study – Physician Questionnaire
Section One Overview of Urinary Incontinence and overactive Bladder
Epidemiology
Presentation
Diagnosis
Referral pattern
Section Two Stress Urinary Incontinence
Diagnosis and treatment of SUI
Non-pharmacological treatment
Pharmacological treatment for SUI
Section Three Overactive Bladder With Urge Symptoms and/or Incontinence
Diagnosis and treatment of UUI
Pharmacological treatment for UUI
Diagnosis and treatment of ‘dry OAB’
Pharmacological treatment for dry OAB
Section Four Mixed Stress/Urge Urinary Incontinence
Diagnosis and treatment of mixed SUI/UUI
Non-pharmacological treatment
Pharmacological treatment for mixed SUI/UUI
Section Five Interstitial Cystitis
Diagnosis and treatment of IC
Pharmacological treatment for IC
Section Six Drug Profiles
Section A: Drug influences on physicians’ choice
Section B: The general treatment of urinary incontinence and overactive bladder
Contributing experts
US
Japan
Europe
APPENDIX B
About Datamonitor
About Datamonitor Healthcare
About the CNS analysis team
Disclaimer